— Receives New Designation for Treatment of Platelet-Activating Anti-Platelet Factor 4 (PF4) Disorders  — Complements FDA Orphan Drug Designation and Fast Track Designation for VLX-1005 Frederick, MD, Aug. 14, 2024 … Read More